FDA Approves First Oral Treatment for Postpartum Depression
The U.S. Food and Drug Administration (FDA) has given the green light to Zurzuvae (zuranolone), marking the first oral medication approved to treat postpartum depression (PPD) in adults.
*If you or someone you know is dealing with postpartum depression, you can find valuable insights and personal experiences in our article on postpartum depression here.
PPD is a severe depressive episode that typically occurs following childbirth, but it can also emerge during late pregnancy. Until now, PPD treatment was only available via intravenous injection in specific healthcare facilities.
What is Zurzuvae and Who is it For?
Zurzuvae is a groundbreaking oral medication designed to alleviate postpartum depression (PPD) symptoms in adults. PPD can bring about feelings of sadness, guilt, and worthlessness, and in severe cases, even thoughts of self-harm or harm to the child. It can also disrupt the mother-infant bond and affect the child’s emotional and physical development.
Who is Zurzuvae Not Suitable For?
While Zurzuvae is a significant advancement, it’s important to note that it may not be suitable for everyone. Individuals taking Zurzuvae should refrain from driving or operating heavy machinery for at least 12 hours after consumption, as it can affect their ability to do so. This medication may also cause drowsiness, dizziness, diarrhea, fatigue, the common cold, urinary tract infections, and even trigger suicidal thoughts and behavior. Pregnant women should use effective contraception while taking Zurzuvae and for one week after discontinuing it.
When is Zurzuvae Available?
Zurzuvae should be taken at a daily recommended dose of 50mg, once daily for 14 days, in the evening, accompanied by a fatty meal.
To find out if Zurzuvae is right for you, consult with your healthcare provider. They can provide personalized guidance based on your specific needs and circumstances.
For more information and in-depth medical details, please refer to the FDA’s official announcement here.
